deucravacitinib
bms
['psoriasis', 'ease,(-please),(-disease),(-incrrease),(-decrease)', 'deucra']
congress #acr22 | philip mease presented the 52 week results from a phase ii trial of deucravacitinib in pts with active #psoriaticarthritis. key efficacy measures were maintained up to 52 weeks, with no new safety signals observed. #psoriasis 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.